Cytokinetics Incorporated (NASDAQ:CYTK) went up by 2.25% from its latest closing price compared to the recent 1-year high of $55.80. The company’s stock price has collected 1.01% of gains in the last five trading sessions. Barron’s reported on 07/19/21 that Cytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors.
Is It Worth Investing in Cytokinetics Incorporated (NASDAQ :CYTK) Right Now?
Plus, the 36-month beta value for CYTK is at 0.93. Opinions of the stock are interesting as 13 analysts out of 15 who provided ratings for Cytokinetics Incorporated declared the stock was a “buy,” while 2 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $62.67, which is $19.52 above the current price. CYTK currently public float of 90.46M and currently shorts hold a 11.10% ratio of that float. Today, the average trading volume of CYTK was 1.13M shares.
CYTK’s Market Performance
CYTK stocks went up by 1.01% for the week, with a monthly drop of -4.37% and a quarterly performance of -8.87%, while its annual performance rate touched 40.05%. The volatility ratio for the week stands at 3.93% while the volatility levels for the past 30 days are set at 4.10% for Cytokinetics Incorporated. The simple moving average for the period of the last 20 days is -0.97% for CYTK stocks with a simple moving average of -1.50% for the last 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Needham repeating the rating for CYTK by listing it as a “Buy.” The predicted price for CYTK in the upcoming period, according to Needham is $58 based on the research report published on December 23rd of the previous year 2022.
Truist, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $60. The rating they have provided for CYTK stocks is “Buy” according to the report published on December 20th, 2022.
UBS gave a rating of “Buy” to CYTK, setting the target price at $80 in the report published on October 11th of the previous year.
CYTK Trading at 3.92% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.67% of loss for the given period.
Volatility was left at 4.10%, however, over the last 30 days, the volatility rate increased by 3.93%, as shares sank -8.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.81% upper at present.
During the last 5 trading sessions, CYTK rose by +1.01%, which changed the moving average for the period of 200-days by +6.94% in comparison to the 20-day moving average, which settled at $43.36. In addition, Cytokinetics Incorporated saw -5.83% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CYTK starting from Blum Robert I, who sale 10,000 shares at the price of $42.43 back on Jan 17. After this action, Blum Robert I now owns 406,412 shares of Cytokinetics Incorporated, valued at $424,300 using the latest closing price.
Malik Fady Ibraham, the EVP Research & Development of Cytokinetics Incorporated, sale 4,000 shares at $40.47 during a trade that took place back on Jan 12, which means that Malik Fady Ibraham is holding 156,589 shares at $161,880 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -264.54 for the present operating margin
- +86.32 for the gross margin
The net margin for Cytokinetics Incorporated stands at -305.72. Equity return is now at value -247.70, with -31.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.45.